Utah Kidney Research Institute | Salt Lake City, UT

Research site

(Unclaimed)

Location

3702 South State Street, Suite 360, Salt Lake City, Utah, United States of America

Site insights

Top conditions

Top treatments

CCX140-B

Vicadrostat

Retatrutide

GFB-887

BI 764198

Lixivaptan

Povetacicept

DMX-200

RO7434656

RG-012

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 13 total trials

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (ACTION3)

DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit...

Enrolling

FSGS

Drug: DMX-200

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO...

Enrolling

Primary IgA Nephropathy

Drug: Placebo

Drug: Sefaxersen (RO7434656)

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is t...

Begins enrollment this month

Focal Segmental Glomerulosclerosis

Drug: Placebo

Drug: BI 764198

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication...

Enrolling

Chronic Kidney Disease

Drug: Vicadrostat

Drug: Empagliflozin

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserv...

Enrolling

Immunoglobulin A Nephropathy

Drug: Placebo (matched to Povetacicept)

Drug: Povetacicept

Locations recently updated

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

This is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in...

Active, not recruiting

Immunoglobulin A Nephropathy

Drug: Sibeprenlimab 400 mg

Drug: Placebo